Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on the shares after the company announced a pipeline ...

Chardan Capital dropped their price objective on 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Finally, Morgan ...

4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price objective trimmed by Morgan Stanley from $8.00 to $6.00 in a report published on Monday,Benzinga reports.The brokerage ...